Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia ( P<0.001 both) -- Immediate memory...)

Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia

P<0.001, both) -- Immediate memory recall declined significantly with zolpidem (P=0.002)

Adverse events were reported in 13 patients with zolpidem and seven patients during placebo and ROZEREM treatment; none were reported as serious.

About ROZEREM

ROZEREM(TM) (ramelteon) is indicated for the treatment of insomnia characterized by difficulty with sleep onset. ROZEREM can be prescribed for long-term use. ROZEREM is the first and only prescription sleep medication that has shown no evidence of abuse or dependence in clinical studies,* and has not been designated as a controlled substance. With the exception of ROZEREM, all other prescription medications indicated for insomnia are classified as Schedule IV controlled substances by the U.S. Drug Enforcement Administration. ROZEREM has a unique therapeutic mechanism of action that selectively targets two receptors located in the brain's suprachiasmatic nucleus (SCN). The SCN is known as the body's "master clock" because it regulates the sleep-wake cycle.

*ROZEREM is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between ROZEREM and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with ROZEREM compared to placebo (N=2082).

Important Safety Information

ROZEREM should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression.

ROZEREM has not been studied in patients with severe sleep apnea, severe COPD, or in children or adolescents. The effects in
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:

(Date:11/9/2009)...PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc...ults from the Company,s Bepreve(TM) (bepotastine b... studies. These results were presented in poster ...n College of Allergy, Asthma & Immunology (ACA...ation titled, "Treatment of Ocular Itching with Be...

(Date:11/9/2009)...., Nov. 9 Thomson Reuters today ... CareFocus, a leading clinical surveillance soluti...ents in real-time and respond immediately to impro...ment. ,, This upgrade is available to current C...CareFocus 2.0 contains several powerful enhancemen...

(Date:11/9/2009)...ov. 9 Arcadia Resources,...novative consumer health care services under the A... Goldsmith to its Board of Directors. Goldsmith w...n from the Board. ,, (Photo: http://www.ne...Goldsmith is the Daniel Paul Professor of Governme...

[0] ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)[0] Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs [0] Arcadia Resources Names Stephen Goldsmith to Board of Directors

...l 17 The SurgiLance safety lancet,an industry-lea...rpose, has,been selected for inclusion in an HIV k... Bundi International Diagnostics. Long established...cets are now part of a major,testing initiative de...,continent., A critical component of the fight ag...

...onstrate Predictable, Extended Exposure with Susta..., CHICAGO, April 17 Data from the first pivotal ...nvestigational compound to treat,Restless Legs Syn... the,symptoms of moderate-to-severe primary RLS co...d when administered once-daily for 12 weeks., Dat...

Other Medicine Technology:SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa 2 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 2 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 3 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 4 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 5 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 6

SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome

(Date:11/9/2009)...es in mood despite similar weight loss , ...fat, low-carbohydrate diet such as the popular Atk...o help people lose pounds over the course of a yea...ill result in long-term improvement in mood, accor...f Internal Medicine . , People on both diets co...

(Date:11/9/2009)... chains are often blamed for the increasing rates ....au however finds that 80% of people think that pa... (PRWEB) November 9, 2009 -- If ... behind Australia’s obesity epidemic, think ...standers. A recent survey commissioned for Fitnes...

(Date:11/9/2009)...ncer Network (NCCN) has posted a draft white paper...for near-term comparative effectiveness clinical e...introduces the NCCN Comparative Therapeutic Index(... the risk-versus-benefit of different treatment op...idelines in Oncology(TM). The paper will be posted...

(Date:11/9/2009)...-- Highlighting a commitment to providing long-ter...ent and digital display technology options, LG Ele...nd Hospital Grade LCD HDTVs this week at the Assoc...nual meeting and exposition (booth #1760). ,, O...ew(TM)" Long-Term Care LCD HDTVs bring a sense of ...

(Date:11/9/2009)... this is so, however , , MONDAY, Nov. ...th very dense breasts have a higher risk of cancer...ows. , Breast density has already been linked w... and experts have suspected that very dense breast... cancer recurrence at the site of the original can...

Breaking Medicine News(10 mins):Health News:To Feel Better, Low-Fat Diet May Be Best 2 Health News:To Feel Better, Low-Fat Diet May Be Best 3 Health News:Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids 2 Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2 Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3 Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4 Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 2 Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 3 Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 4 Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 5 Health News:Dense Breasts Raise Risk of Cancer Recurrence 2 Health News:Dense Breasts Raise Risk of Cancer Recurrence 3

[0] To Feel Better, Low-Fat Diet May Be Best [1] Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids [0] NCCN Posts Comparative Effectiveness White Paper for Public Comment [0] LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs [0] Dense Breasts Raise Risk of Cancer Recurrence

... Travellers urged to seek... London, UK (PRWeb UK) May 18...epatitis B endemic areas, reveals that over 55 per...ide the Eurozone, such as Egypt and Turkey,(3) whe...

...ounger, active patients will benefit from cement-l...ay 18 (HealthDay News) -- Total hip replacements t...- twice as long as previous versions, a new study ... to replace the bone that fits into the hip socket...

... ORLANDO, Fla., May 18 Combining two chemotherapy... who have metastatic HER2+ breast cancer may offer...ons. , , At the 45th Annual Meeting of the Amer...lbine, and trastuzumab offers a treatment option t...

... ORLANDO, May 18 A pill used for nerve pain offer...esearchers report at the 45th Annual Meeting of th.... , , They say the agent, pregabalin, decreased h..., an older, related drug, as well as newer classes...

... CPF Recognized for Advancing Research and Patient...ition for Pulmonary Fibrosis (CPF) today announced...s (ATS) International conference in San Diego, Cal...rd for a partner grant program with ATS that, to d...

...ut U.S. health officials say the disease is no mor...ay 18 (HealthDay News) -- While most cases of swin...he death rate from the new H1N1 virus is slightly ...tle bit higher than seasonal influenza, but not ne...

GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially fatal virus Improved Hip Implants Can Last 20 Years Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu

...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...

Medicine Products:

Free Prostate Specific Antigen Free Plasma Hemoglobin Free Kappa Light Chains (Bence Jones Protein), Urine by Immunofixation Elecrophoresis, Quantitative Free Homocystine (Plasma)

( P<0.001 both) -- Immediate memory...)Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia,Health